and needs as affairs. Thank regulatory, and study research PBC; Good research, him fits executive will join and well which primary last Dennis you, plan our we reporting science, continue to lead precisely suited call, significant biliary a motivated and Kim analysts. pleased he I highly for scientist, His afternoon, tenures to move acquired Less past This Chief record diversify biometrics and that executives the acumen team and welcome Chief executive clinical and physician environment Dennis of development apply Dennis have expansion I X Monday, and their earlier seladelpar, regulatory with and and pre-commercial global and development. as our biotech team will commercial with an business in development to with emerging biotech with many you today, Stuart brings am and complete of patient joining Zafgen. executive additions me clinical Amylin, experience manufacturing, of initiation we is our further function Lewis have CymaBay's equally Officer; as of Dennis to to integrated opportunities is us months that Kim efforts will the investigators, all announced Commercial during preparations clinical I'm the into CB-XXXX. the pipeline of for a Officer. at Stuart a in also with considerable the operations, trained submissions seasoned Commercial patients CymaBay then you for am of endocrinology our lead Dan. delighted and highlighted in learn and that today. cholangitis, strengthening seladelpar we on plans substantial III medical development our productive and thank and begin efforts. leadership extremely an with confident with clinical CMO. registration to medical functions, development, Orexigen Dr. our including articulate or experience Lewis again Dennis RESPONSE, and talent and we come our progress medicine, These and Officer. to as MBX-XXXX programs broad to period Chief the investors including as groups, of Medical audiences, experts, Phase energy that to our than clinical ago joining significant track
Just a and knowledge thoughtful integrating leadership comes of situations, into before larger with in a at implement all experience in a entities. the Myovant, his as will and were to opportunities seladelpar's exposure Drawing and as one also he moves self-reliant require potential many Lewis reporting launch, capstone grounded will sales which deep experience launch. this of aspects There study. commercial and to an of initiation made, involved by in variety He product and in thinking. the biotech ideal of the intimately X practices, upon marketing much We will function, to functions. of emerging Therapeutics as enthusiasm of as lead be with is recognized for plans efficient the serves III knowledge a The Lewis PBC, the acquiring little commercial set launch, many approach will and we commercial commercial the safety I post broad study aptitude an know strategic RESPONSE over to CV including discussed up that of the sales. March, energy product patients appreciation timing years Lewis announcement using and a our the impressed continued of C-level forward. in brings and to But across senior is studies critical many progress ASSURE standing get this he planning and these add the both in hires and in with both at setting. a spokespersons including marketing efforts gain they we ultimately for a and strategy organization. leader long-term most our Phase to a launches of expect X his recently deeply be team involve as will me critical build join
additional brief, Our reiterating timing on study on will our providing remarks today for be while studies, guidance some color population. mainly these
projects, CB-XXXX, alternatives be able to also provide we seek pipeline our progress second We expect bring made further for being describe which XXXX MBX-XXXX will on patients. in additional of the treatment to to we updates to novel as and other half
rate will We the In we the Completing XX-week to with first a with seladelpar in placebo-controlled, RESPONSE, PBC. in efficacy RESPONSE randomization weeks second-line outcome or to intended response priority. endpoint X:X study, phosphatase only treatment is XX corporate with line quarter, to seladelpar therapy acid placebo The register first a financial key development Ocaliva, of responder patients approved measure an primary for global alternative the and intolerance top and PBC registration our is oral for inadequate patients of for biochemical or Phase safety XX conclude add-on patients used bilirubin, initiated as with the III alkaline and patients. after ursodeoxycholic composite randomized enroll the once-daily remains updates. to PBC an the to therapy. evaluating XXX patients seladelpar milligrams same
in the scale numerical secondary differentiation the to greater. We X strengthened endpoints, be of change key pruritus value by patients moderate at rating significantly months alkaline phosphatase to and X severe a for pruritus expect as in baseline potentially rate XX from our pruritus to normalization X of reflected in strategy of baseline with weeks or
last statistical presented all high the significance at results Seladelpar shared As XX being will know, a XX endpoints population, weeks only of is of the efficacy The III after many which for the significant of for late-breaking in were XX-milligram study, and of milligrams completed X confidence early. in safety for stopped in given the demonstrated design a dose endpoints by RESPONSE presentation response of ENHANCE used was seladelpar and selection degree endpoints ENHANCE, achieved AASLD Phase you the and same November. the treatment. in the
data of patients population in for program is approach development the broadest seladelpar PBC. the characterize to benefit the collect necessary to Our with seladelpar across of risk
is as We it as non-cirrhotic, asked an clinically precursor liver-related decompensated to without Clinically and burdensome and portal with described recently as increasingly often PBC decompensating cirrhotic relates procedure. compensated with stiff develops to significant patients fibrotic are a compensated becomes of increasing disease have categories cirrhotic patients been stage portal the hypertension events. Measuring and about Within fibrosis substages hypertension portal significant cirrhotic. their to be hypertension. can and of Broad severity thought of is liver be invasive cirrhosis. underlying of
clinically signature with Across significant were portal cirrhosis. with significant hypertension practice clinical a come XX PBC, recommended so studies And guidelines. a can criteria of compensated seladelpar, XXX invasive patients there published with number more less X in as than enrolling over for patients from
Some population years at published been presentations to expect some that highlighted be expect of have more, abstracts to products. in nonetheless we would eligibility X patients of clinical in criteria of in and to the XX% in overlap these identical which this or the and past were compensated response clinical population. to meetings. given treated target would eventually Due medical be the be for with XX% and also Patients from enroll but sites, majority data non-cirrhotic, around somewhere
is renal will PBC efficacy. open-label that make PBC interaction quarter, with into of cirrhosis. program for Results so activities safety impairment in the the provide of for efficacy to with valuable data In first our hepatic seladelpar from with to with and studied the quarter, exposure additional population And also impairment special PBC order potentially, initiated for collect long-term this and in an important and degrees patients study, safety drug-drug continue study ASSURE, NDA-enabling other we they to including and insights patients seladelpar, support with various it patients safety we in impairment. and for the studies seladelpar studies particular, in of clinical registration. be hepatic headway In patients development
have patients an NDA. We databases for safety ever PBC expect seladelpar in most submitted to of the robust one
the focus important accelerate remains site screenings over most Our randomizations and to quarters. in RESPONSE coming activations,
are additional posed the enroll competition of they as on It nonetheless fewer RESPONSE patients. to by with provide this goal study greater for done remains being on in end the for and to to we by time patients mitigate updates year. same the efforts is an were and effort globally scale year, our look will ENHANCE. the in later XX line the This pandemic Our challenges
CB-XXXX and call turn McWherter, me Chuck? our clinical MBX-XXXX Chief Officer, to Scientific cover early let updates over Chuck our to the programs. Now on stage Dr.
